GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Capital Expenditure

Gan & Lee Pharmaceuticals Co (SHSE:603087) Capital Expenditure : ¥-461.53 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Gan & Lee Pharmaceuticals Co's cash flow for capital expenditures for the three months ended in Mar. 2025 was ¥-158 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-461.53 Mil.

Gan & Lee Pharmaceuticals Co Capital Expenditure Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Capital Expenditure Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -582.14 -692.08 -983.44 -553.06 -440.80

Gan & Lee Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.14 -69.17 -88.45 -146.04 -157.87

Gan & Lee Pharmaceuticals Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-461.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan & Lee Pharmaceuticals Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Capital Expenditure
Comparable Companies
SZSE:300888 SZSE:002432 SHSE:688301 SZSE:002294 SHSE:688050 SZSE:300677 SZSE:300595 SZSE:300573 SHSE:688289 SHSE:688029 ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Website
http://www.ganlee.com
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines